Wuxi Biologics highlighted their highly integrated and scaled platform, allowing for end-to-end research, development and ...
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary ...
Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects209 new integrated projects in 2025 set a new record, with approximately 50% ...
In-vitro and in-vivo data indicate SnapShot enables drug developers to produce high concentration, high dose, subcutaneous formulations of mAbs and biologics Surf Bio CEO, Bryan Mazlish, to deliver ...
- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and manufacturing of ...
SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of ...
For decades, therapeutic monoclonal antibody (mAb) production relied on traditional batch-based manufacturing using stainless steel systems. But as biopharmaceutical pipelines grow to meet rising ...
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains the critical challenges of developing bispecific ...
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been honored with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results